Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Unified data also improves AI outputs. For example, by drawing up-to-date information from a variety of an organization’s ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Recent changes to federal guidance on COVID vaccinations have providers worried about what’s to come. “We have opened a door ...